ADICON HOLDINGS (09860) announced its interim results for the six months ended June 30, 2025. The group recorded revenue of RMB 1.271 billion, representing a decrease of 13.31% compared to the same period last year. Net profit attributable to shareholders of the parent company reached RMB 27.273 million, down 73.15% year-over-year, with earnings per share of RMB 0.04.

The company's total revenue amounted to RMB 1.27 billion, declining 13.3% year-over-year. Despite short-term pressures from economic cycle adjustments and policy changes, the company's diversified business portfolio continued to demonstrate resilience and supported positive development momentum across multiple segments.

During the reporting period, co-construction business revenue grew 30% year-over-year, achieving a four-year compound annual growth rate (CAGR) of 48%. This growth was primarily driven by the successful implementation of projects with several large tertiary hospitals. Looking ahead to the second half of the year, the company plans to deepen strategic partnerships with leading medical institutions and advance more landmark projects.

The CRO (Contract Research Organization) business recorded revenue growth of 18% year-over-year. Through deep collaboration with leading domestic and international pharmaceutical companies, the company continues to consolidate its advantageous position in the diabetes field, achieved strong performance in the NASH (Non-alcoholic Steatohepatitis) sector, and realized innovative breakthroughs in solid tumor treatment, expanding into new business territories.